Transcatheter aortic valve replacement (TAVR) with balloon-expandable and self-expanding valves is now an accepted alternative to surgical aortic valve replacement (SAVR) in the treatment of symptomatic severe aortic stenosis in patients at increased risk for surgery.
1,2 The Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM), used alone or in part to select patients for TAVR, has decreased over time since the first randomized trial of balloon-expandable TAVR with a study mean of 11.6%,
3 to the 2016 study in intermediate-risk patients with a mean of 5.8%.
4 Transcatheter aortic valve replacement using a self-expanding valve (CoreValve bioprosthesis; Medtronic) has shown superior survival compared with SAVR at 1 year
5 and 2 years
6 in patients with a mean STS PROM score of 7.4%.